You just read:

SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy

News provided by

SentoClone

05 Jun, 2013, 12:15 BST